Bijuva

Understanding Bijuva: Brand Heritage and Manufacturing

Bijuva is a specialized pharmaceutical product used for hormone replacement therapy (HRT), specifically formulated as the first FDA-approved bioidentical hormone combination of estradiol and progesterone in a single oral capsule. The brand was developed using advanced pharmaceutical technology to provide a streamlined solution for women managing symptoms of menopause. Its entry into the market marked a significant development in women's healthcare, focusing on bioidentical hormones that are molecularly identical to those produced naturally by the body.

Corporate Ownership and Global Presence

The brand was originally developed and brought to market by TherapeuticsMD, Inc., an American pharmaceutical company focused on women's health. In a significant strategic shift in late 2022 and early 2023, the brand and its associated assets were acquired by Mayne Pharma. This acquisition placed the product under the stewardship of a global pharmaceutical entity based in Australia, which specializes in specialty and generic medicines. While the commercial rights and brand ownership are consolidated under Mayne Pharma, the production of complex hormonal medications like Bijuva often involves a global supply chain utilizing specialized pharmaceutical manufacturing facilities across North America and Europe to ensure high standards of quality and regulatory compliance.